Letter: Pyrimethamine toxicity
Related Articles
- Pyrimethamine overdose. // Reactions Weekly;12/17/2011, Issue 1382, p29
The article describes the case of a neonate who developed various toxicities after administration of pyrimethamine overdoses for asymptomatic congenital toxoplasmosis.
- Pulmonary toxicity of malaria prophylaxis. Davidson, A.C.; Bateman, C.; Shovlin, C.; Marrinan, M.; Burton, G.H.; Cameron, I.R. // BMJ: British Medical Journal (International Edition);11/12/88, Vol. 297 Issue 6658, p1240
Examines the pulmonary toxicity of malaria prophylaxis. Impact of toxicity on other body organs; Occurrence of systemic illness after pyrimethamine-sulfadoxine treatment; Importance of lung biopsy for the determination of eosinophilic pneumonia.
- Letters. Elden, Susan; Jagoe, George; Misiorowska, Aleksandra // Africa Health;Jul2013, Vol. 35 Issue 5, p15
Several letters to the editor are presented on topics including polio eradication in Africa and use of suiphadoxine and pyrimethamine in preventing malaria in children under 5.
- Pneumocystis carinii Pneumonia Treated with Pyrimethamine and Sulfadiazine. Kirby, Henry B.; Kenamore, Bruce; Guckian, James C. // Annals of Internal Medicine;Oct71, Vol. 75 Issue 4, p505
Provides information on a study on the results of pyrimethamine and sulfadiazine therapy in adults with Pneumocystis carinii. Evaluation of the toxicity of the drugs; Patients of different ethnic backgrounds admitted for Pneumocystis carinii pneumonia; Information on antimicrobial agents.
- Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria. Ringwald, P. // BMJ: British Medical Journal (International Edition);5/22/2004, Vol. 328 Issue 7450, p1259
Presents a letter to the editor of the May 22, 2004 issue of the "British Medical Journal," regarding the use of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria. Assessment of the efficacy of antimalarial drugs by the World Health Organization; Evidence of the resistance to the...
- Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria. White, Nicholas // BMJ: British Medical Journal (International Edition);5/22/2004, Vol. 328 Issue 7450, p1259
Presents a letter to the editor of the May 22, 2004 issue of the "British Medical Journal," regarding the use of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria. Resistance of malaria in Malawi to the combination drug.
- Defending the Use of Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment for Malaria in Pregnancy: A Short-Sighted Strategy. Harrington, Whitney E.; Fried, Michal; Duffy, Patrick E.; Gutman, Julie; Taylor, Steve; Meshnick, Steven R.; ter Kuile, Feiko O. // Journal of Infectious Diseases;2/1/2016, Vol. 213 Issue 3, p496
A letter to the editor is presented in response to the article related to an observational study of sulfadoxine-pyrimethamine for intermittent preventive treatment for malaria in pregnancy (SP-IPTp) in Malawi, Africa by J Gutman and colleague.
- Single-Dose Sulfadoxine-Pyrimethamine in Intermittent Preventive Treatment of Malaria. Gosling, Roly D.; Schellenberg, David M.; Chandramohan, Danial // Journal of Infectious Diseases;6/1/2006, Vol. 193 Issue 11, p1609
A letter to the editor is presented in response to the article titled "Parasitological Rebound effect and Emergence of Pyrimethanine Resistance in Plasmodium Falciparum After Single-Dose Sulfadoxine-Pyrimethamine," published in a 2006 issue of the "Journal of Infectious Diseases."
- The potential role of azithromycin in the treatment or prophylaxis of toxoplasmosis. Chang, H. R. // International Journal of STD & AIDS;Jan1996 Supplement 1, Vol. 7, p18
Infection with Toxoplasma gondii is the most common parasitic infection worldwide with an estimated prevalence of 1-2 billion people. The risk of developing severe toxoplasmosis is higher for immunocompromised individuals and fetuses of mothers who have acquired a primo-infection. The current...
- Cardiovascular Toxicity of Valdecoxib. Ray, Wayne A.; Griffin, Marie R.; Stein, C. Michael // New England Journal of Medicine;12/23/2004, Vol. 351 Issue 26, p2767
A letter to the editor is presented discussing the cardiovascular toxicity of valdecoxib.
